Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Danuglipron on Rosuvastatin and Midazolam PK in Obesity
NCT04621227Phase 1Completed
- Sponsor
- Pfizer
- Start
- Dec 2020
- Primary completion
- May 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of danuglipron in obesity, sponsored by Pfizer. Primary endpoints: Area Under the Plasma Concentration-time Profile From Time 0 to Last Quantifiable Concentration (AUClast) of Rosuvastatin at Day 1 and Area Under the Plasma Concentration-time Profile From Time 0 to Last Quantifiable Concentration (AUClast) of Midazolam at Day 1. Started Dec 2020; status: completed.
02
Drugs
danuglipron
03
Conditions
obesity
Beyond the preview
Go deeper on NCT04621227.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04621227.